Four of eight appointees to Robert F. Kennedy Jr.'s health panel own stock in major pharmaceutical companies, according to conflict-of-interest waivers obtained by The New York Times. Dr. Patrick K. Hunter, Dr. Ronald P.
Karlsberg, Dr. Venkatesh L. Murthy, and Dr. Dennis W. Wulfeck all hold investments in firms like Eli Lilly, Johnson & Johnson, Merck, and Pfizer.
Their financial ties span cardiology, diagnostics, and pharmaceuticals, raising concerns about scientific rigor and public trust. Historically, task force candidates were required to divest such holdings. The waivers, granted under new ethics rules following a Supreme Court ruling, allow these members to serve despite potential conflicts.
The task force influences insurance coverage and medical guidelines for services including colonoscopies and HIV prevention. While some appointees claim managed portfolios, the disclosures highlight a significant shift from past standards where such investments barred appointment. The panel's recommendations impact drug profitability and doctor decisions nationwide.
Source: New York Times Top Stories · Summarized by HeadlinesBriefing